AstraZeneca announces new data from portfolio, pipeline at ASCO meeting

AstraZeneca (AZN) announces new data across its portfolio and pipeline at the American Society of Clinical Oncology, ASCO, Annual Meeting, 29 May to 2 June 2026. EMERALD-3: Phase III trial of Imfinzi in combination with Imjudo, with or without lenvatinib, and transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma eligible for embolisation. CARES: Phase III clinical programme of anselamimab, a potential first-in-class anti-fibril therapy from Alexion, AstraZeneca Rare Disease, in newly diagnosed patients with light chain amyloidosis receiving standard of care for underlying plasma cell dyscrasia. SERENA-6: Final progression-free survival 2 results and circulating tumour DNA clearance data linked to longer-term efficacy outcomes from the SERENA-6 Phase III trial of camizestrant. BLUESTAR: Updated safety and efficacy results from the BLUESTAR Ph I/IIa trial of the B7-H4-directed ADC puxitatug samrotecan in patients with relapsed/metastatic B7-H4-positive endometrial and ovarian cancer who progressed on prior standard-of-care therapy. PRIMAVERA: Safety and preliminary efficacy from the first-in-human Phase I PRIMAVERA trial of the protein arginine methyltransferase 5 inhibitor AZD3470 as monotherapy in relapsed/refractory classic Hodgkin lymphoma. Phase I initial results for NT-175 T-cell receptor therapy in TP53 R175H-mutated unresectable, advanced and/or metastatic solid tumours including pancreatic adenocarcinoma. TROPION-Breast02: Additional efficacy endpoints from the TROPION-Breast02 Phase III trial of Datroway as 1st-line treatment for patients with locally recurrent inoperable or metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitors. DESTINY-Breast09: Exploratory analysis of treatment duration and clinical outcomes by complete response, partial response or stable/progressive disease in the DESTINY-Breast09 Phase III trial of Enhertu in combination with pertuzumab for the 1st-line treatment of patients with HER2-positive metastatic breast cancer. POTOMAC: Five-year overall survival and patient-reported outcomes from the Phase III POTOMAC trial of Imfinzi plus Bacillus Calmette-Guerin induction and maintenance therapy in patients with high-risk non-muscle-invasive bladder cancer.